Kinase inhibition, competitive binding and proteasomal degradation: Resolving the molecular function of the suppressor of cytokine signaling (SOCS) proteins

Immunological Reviews

Volumn 266, Issue 1, 2015, Pages 123-133

  Linossi, Edmond M ^a,b   Nicholson, Sandra E ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cytokine; JAK; SOCS

Indexed keywords

CYTOKINE; PHOSPHOTRANSFERASE; PHOSPHOTYROSINE; PROTEASOME; PROTEIN SH2; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING COMPETITION; ENZYME INHIBITION; HUMAN; IMMUNOREGULATION; INFLAMMATION; INTRACELLULAR SIGNALING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FAMILY; UBIQUITINATION; ANIMAL; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; BINDING, COMPETITIVE; CYTOKINES; HUMANS; MICE; MICE, KNOCKOUT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84931032489     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12305     Document Type: Article

References (87)

1. Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors 2012;30:88-106.
2. Chen E, Staudt LM, Green AR. Janus kinase deregulation in leukemia and lymphoma. Immunity 2012;36:529-541.
3. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-170.
4. Yoshimura A, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995;14:2816-2826.
5. Starr R, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-921.
6. Naka T, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-929.
7. Endo TA, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387:921-924.
8. Hilton DJ, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 1998;95:114-119.
9. Zhang JG, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 1999;96:2071-2076.
10. Kamura T, et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 1998;12:3872-3881.
11. Bullock AN, Debreczeni JE, Edwards AM, Sundstrom M, Knapp S. Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci USA 2006;103:7637-7642.
12. Babon JJ, et al. Structure of mouse SOCS3 reveals the structural basis of the extended SH2 domain function and identifies an unstructured insertion that regulates in vivo stability. Mol Cell 2006;22:205-216.
13. Liongue C, O'Sullivan LA, Trengove MC, Ward AC. Evolution of JAK-STAT pathway components: mechanisms and role in immune system development. PLoS ONE 2012;7:e32777.
14. Arbouzova NI, Zeidler MP. JAK/STAT signalling in Drosophila: insights into conserved regulatory and cellular functions. Development 2006;133:2605-2616.
15. Alexander WS, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999;98:597-608.
16. Roberts AW, et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signalling (SOCS)-3. PNAS 2001;98:9324-9329.
17. Croker BA, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003;4:540-545.
18. Robb L, et al. Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. Proc Natl Acad Sci USA 2005;102:16333-16338.
19. Babon JJ, Nicola NA. The biology and mechanism of action of suppressor of cytokine signaling 3. Growth Factors 2012;30:207-219.
20. Babon JJ, et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 2012;36:239-250.
21. Kershaw NJ, et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 2013;20:469-476.
22. Wormald S, et al. The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling. J Biol Chem 2006;281:11135-11143.
23. Yasukawa H, et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003;4:551-556.
24. Lang R, et al. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 2003;4:546-550.
25. Brender C, et al. SOCS5 is expressed in primary B and T lymphoid cells but is dispensable for lymphocyte production and function. Mol Cell Biol 2004;24:6094-6103.
26. Seki Y, et al. Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci USA 2002;99:13003-13008.
27. Sasaki A, et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 1999;4:339-351.
28. Yasukawa H, et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999;18:1309-1320.
29. Bullock AN, Rodriguez MC, Debreczeni JE, Songyang Z, Knapp S. Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure 2007;15:1493-1504.
30. Babon JJ, et al. The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J Mol Biol 2008;381:928-940.
31. Babon JJ, et al. Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain. FEBS J 2005;272:6120-6130.
32. Liu BA, Engelmann BW, Nash PD. The language of SH2 domain interactions defines phosphotyrosine-mediated signal transduction. FEBS Lett 2012;586:2597-2605.
33. Zadjali F, et al. Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. J Biol Chem 2011;286:480-490.
34. Nicholson SE, et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J 1999;18:375-385.
35. Nicholson SE, et al. Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci USA 2005;102:2328-2333.
36. Kario E, et al. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem 2005;280:7038-7048.
37. Calvisi DF, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117:2713-2722.
38. Kedzierski L, et al. Suppressor of cytokine signaling 4 (SOCS4) protects against severe cytokine storm and enhances viral clearance during influenza infection. PLoS Pathog 2014;10:e1004134.
39. Bayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P. Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem 2004;279:12249-12259.
40. Kazi JU, Sun J, Phung B, Zadjali F, Flores-Morales A, Ronnstrand L. Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3. J Biol Chem 2012;287:36509-36517.
41. Greenhalgh CJ, et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 2002;277:40181-40184.
42. Matsumoto A, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997;89:3148-3154.
43. Verdier F, et al. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein. J Biol Chem 1998;273:28185-28190.
44. Eulenfeld R, et al. Interleukin-6 signalling: more than Jaks and STATs. Eur J Cell Biol 2012;91:486-495.
45. Nicholson SE, et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2- binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 2000;97:6493-6498.
46. Forrai A, et al. Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cells. Stem Cells 2006;24:604-614.
47. Liu E, Cote JF, Vuori K. Negative regulation of FAK signaling by SOCS proteins. EMBO J 2003;22:5036-5046.
48. Le Y, et al. SOCS3 protein developmentally regulates the chemokine receptor CXCR4-FAK signaling pathway during B lymphopoiesis. Immunity 2007;27:811-823.
49. Gao Y, Cimica V, Reich NC. Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3. J Biol Chem 2012;287:20904-20912.
50. Liu L, Gao Y, Qiu H, Miller WT, Poli V, Reich NC. Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 2006;25:4904-4912.
51. Lee SH, et al. Suppressor of cytokine signaling 2 regulates IL-15-primed human NK cell function via control of phosphorylated Pyk2. J Immunol 2010;185:917-928.
52. Choi YB, Son M, Park M, Shin J, Yun Y. SOCS-6 negatively regulates T cell activation through targeting p56lck to proteasomal degradation. J Biol Chem 2010;285:7271-7280.
53. Piganis RA, et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 2011;286:33811-33818.
54. Feng ZP, Chandrashekaran IR, Low A, Speed TP, Nicholson SE, Norton RS. The N-terminal domains of SOCS proteins: a conserved region in the disordered N-termini of SOCS4 and 5. Proteins 2012;80:946-957.
55. Ward JJ, Sodhi JS, McGuffin LJ, Buxton BF, Jones DT. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol 2004;337:635-645.
56. Oldfield CJ, Dunker AK. Intrinsically disordered proteins and intrinsically disordered protein regions. Annu Rev Biochem 2014;83:553-584.
57. Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 2005;6:197-208.
58. Linossi EM, et al. Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. PLoS ONE 2013;8:e70536.
59. Stec WJ, Zeidler MP. Drosophila SOCS Proteins. J Signal Transduct 2011;2011:894510.
60. Stec W, Vidal O, Zeidler MP. Drosophila SOCS36E negatively regulates JAK/STAT pathway signaling via two separable mechanisms. Mol Biol Cell 2013;24:3000-3009.
61. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005;6:9-20.
62. Ciechanover A, Stanhill A. The complexity of recognition of ubiquitinated substrates by the 26S proteasome. Biochim Biophys Acta 2014;1843:86-96.
63. Babon JJ, Sabo JK, Zhang JG, Nicola NA, Norton RS. The SOCS box encodes a hierarchy of affinities for Cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression. J Mol Biol 2009;387:162-174.
64. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009;78:399-434.
65. Kershaw NJ, Laktyushin A, Nicola NA, Babon JJ. Reconstruction of an active SOCS3-based E3 ubiquitin ligase complex in vitro: identification of the active components and JAK2 and gp130 as substrates. Growth Factors 2014;32:1-10.
66. Linossi EM, Nicholson SE. The SOCS box-adapting proteins for ubiquitination and proteasomal degradation. IUBMB Life 2012;64:316-323.
67. Ram PA, Waxman DJ. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 1999;274:35553-35561.
68. Greenhalgh CJ, et al. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol 2002;16:1394-1406.
69. Banks AS, et al. Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest 2005;115:2462-2471.
70. Boyle K, et al. The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood 2007;110:1466-1474.
71. Boyle K, et al. Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation. Cell Signal 2009;21:394-404.
72. Zhang JG, et al. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc Natl Acad Sci USA 2001;98:13261-13265.
73. Cimica V, Reich NC. Nuclear trafficking of STAT proteins visualized by live cell imaging. Methods Mol Biol 2013;967:189-202.
74. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014;346:1258096.
75. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 2014;32:347-355.
76. Strebovsky J, Walker P, Lang R, Dalpke AH. Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus. FASEB J 2011;25:863-874.
77. Baetz A, Koelsche C, Strebovsky J, Heeg K, Dalpke AH. Identification of a nuclear localization signal in suppressor of cytokine signaling 1. FASEB J 2008;22:4296-4305.
78. Gielen V, et al. Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons. J Allergy Clin Immunol 2015. doi:10.1016/j.jaci.2014.1011.1039.
79. Koelsche C, Strebovsky J, Baetz A, Dalpke AH. Structural and functional analysis of a nuclear localization signal in SOCS1. Mol Immunol 2009;46:2474-2480.
80. Hwang MN, et al. The nuclear localization of SOCS6 requires the N-terminal region and negatively regulates Stat3 protein levels. Biochem Biophys Res Commun 2007;360:333-338.
81. Kremer BE, Adang LA, Macara IG. Septins regulate actin organization and cell-cycle arrest through nuclear accumulation of NCK mediated by SOCS7. Cell 2007;130:837-850.
82. Krebs DL, et al. Development of hydrocephalus in mice lacking SOCS7. Proc Natl Acad Sci USA 2004;101:15446-15451.
83. Krebs DL, et al. SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol 2002;22:4567-4578.
84. Cui Q, et al. Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma. Hepatology 2008;47:105-112.
85. Liu L, et al. Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma. Gene Ther 2013;20:84-92.
86. Jo D, Liu D, Yao S, Collins RD, Hawiger J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med 2005;11:892-898.
87. DiGiandomenico A, Wylezinski LS, Hawiger J. Intracellular delivery of a cell-penetrating SOCS1 that targets IFN-gamma signaling. Sci Signal 2009;2:ra37.